Development of a Targeted Gene-Delivery System Using Escherichia coli

Area of Science:

• Microbiology
• Biotechnology
• Oncology

Background:

• Targeted gene therapy offers a promising approach for treating cancer.
• Non-phagocytic cancer cells present a challenge for conventional gene delivery systems.
• Microbial delivery systems provide a novel strategy for targeted cancer therapy.

Purpose of the Study:

• To demonstrate the feasibility of using engineered Escherichia coli for targeted gene delivery to HER2/neu-positive cancer cells.
• To develop a microbial system capable of delivering a transgene (eukaryotic GFP) to specific cancer cell types.
• To assess the efficacy of a surface-displayed anti-HER2/neu affibody for targeting cancer cells.

Main Methods:

• Engineering an E. coli strain to display an anti-HER2/neu affibody on its surface.
• Introducing a programmed lysis system (phage ϕX174 gene E) into the engineered E. coli for gene release.
• Infecting HER2/neu-positive cancer cells with the engineered E. coli to deliver the GFP transgene.

Main Results:

• The engineered E. coli successfully targeted HER2/neu-positive cancer cells.
• Expression of the eukaryotic GFP transgene was observed in targeted cancer cells.
• Approximately 3% of HER2/neu-positive cancer cells infected with the engineered E. coli expressed GFP.

Conclusions:

• Escherichia coli can be engineered as a targeted gene-delivery system for non-phagocytic cancer cells.
• The developed microbial system demonstrates feasibility for HER2/neu-targeted gene therapy.
• This approach shows potential for advancing novel cancer treatment strategies.